The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig
- PMID: 1933135
- PMCID: PMC1907803
- DOI: 10.1111/j.1476-5381.1991.tb09851.x
The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig
Abstract
1. The pharmacokinetic interaction between cyclosporin (CsA) and erythromycin has been studied in the weanling pig model. 2. Blood CsA and metabolite-1 (M1) concentrations were monitored by high performance liquid chromatography in portal, hepatic and jugular venus blood before and after treatment with erythromycin stearate for 7 days. 3. Erythromycin significantly increased maximum concentration (Cmax) and area under the concentration-time curve from 0 to 24 h (AUC) of CsA in the peripheral circulation. This was accompanied by a significant reduction in the hepatic extraction ratio calculated from portal and hepatic Cmax and AUC data. 4. The extraction ratio appears to be concentration-dependent in that values derived from Cmax (high concentrations) were greater than those from AUC (average concentrations). 5. Time to Cmax (tmax) and t1/2 of CsA were essentially unchanged and no significant changes were observed in peripheral M1 kinetics apart from a small increase in tmax. 6. The pharmacokinetic changes observed in the pig suggest that the CsA-erythromycin interaction is caused by inhibition of hepatic metabolism and the impact of inhibition is greatest during first-pass when CsA concentrations are at their highest.
Similar articles
-
Cyclosporin-erythromycin interaction in normal subjects.Br J Clin Pharmacol. 1987 Jun;23(6):776-8. Br J Clin Pharmacol. 1987. PMID: 3606938 Free PMC article.
-
Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.Bone Marrow Transplant. 2000 Sep;26(5):545-51. doi: 10.1038/sj.bmt.1702545. Bone Marrow Transplant. 2000. PMID: 11019845
-
Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers.J Clin Pharmacol. 2003 Oct;43(10):1168-76. doi: 10.1177/0091270003257227. J Clin Pharmacol. 2003. PMID: 14517200 Clinical Trial.
-
Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.Clin Pharmacokinet. 2002;41(1):59-69. doi: 10.2165/00003088-200241010-00005. Clin Pharmacokinet. 2002. PMID: 11825097 Clinical Trial.
-
Clinical pharmacokinetics of mizolastine.Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.
Cited by
-
Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.Eur J Drug Metab Pharmacokinet. 2016 Oct;41(5):567-74. doi: 10.1007/s13318-015-0267-4. Epub 2015 Apr 22. Eur J Drug Metab Pharmacokinet. 2016. PMID: 25898809 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources